Product category:
Pharmaceutical Processing News
News Release from: Frost and Sullivan | Subject: B934-52
Edited by the Processingtalk Editorial
Team on 09 August 2006
Advances in Insulin delivery poised for
growth
Innovative, non-invasive methods to deliver insulin are poised to transform diabetes management, according to Frost and Sullivan research
Innovative, non-invasive methods to deliver insulin are poised to transform diabetes management Despite concerns about their safety and efficacy, an eager diabetic community is expected to support research into novel technologies that promote greater compliance and therefore improved disease management
This article was originally published on Processingtalk on 7 Feb 2003 at 8.00am (UK)
Related stories
The HIV/AIDS Therapies Market
While antiretroviral drugs in existing categories continue to be the mainstay of the HIV/AIDS therapies market in the United States, the development of new drugs offers exciting growth prospects
The European breast cancer pharmaceuticals market
The quest for a breast cancer wonder drug, and improved survival rates, continue to pump up business in the breast cancer pharmaceutical industry
Accordingly, the revenue potential across Europe of non-invasive insulin, particularly inhaled insulin, will be considerable.
Frost and Sullivan finds that the European Inhaled Insulin Market will earn revenues of US$49.3 million in 2006 and estimates this to reach US$611.7 million in 2012.
"Compliance is currently a major drawback in current diabetes delivery devices, with several patients suffering from Type 2 diabetes irregularly following or, in some cases, even discontinuing their insulin therapy due to pain or fear of injections," says Frost and Sullivan Research Analyst Sylvia Miriyam Findlay.
Further reading
Proteomics sample preparations markets
Integrated, customised, and validated research solutions for proteomics analyses and drug discoveries will fuel growth in the sample preparations market, according to the latest market resaerch report
Portfolio management in pharmaceutical market
Portfolio management carves a niche for itself in the resource-constrained pharmaceutical market, based on the need to identify and prioritise the most profitable projects in the R and D pipeline
Pharma rethinks traditional product marketing
A resurgent disease management sector will compel pharmaceutical companies to market products as constituents of packages of care, re-directing their sales efforts towards planners rather than doctors
"Through more convenient drug delivery methods, pharmaceutical companies, regulatory bodies and other government institutions can introduce better diabetes care and reduce costs related to diabetic complications caused by poor compliance".
At present, several methods of non-invasive insulin delivery, including oral, transdermal, nanotechnology-based and gene therapy-based ones, are under research.
Efforts are also on to develop a diabetes vaccine.
One of the most promising modes of delivery under investigation is that of inhaled insulin.
Leading participants in the diabetes medication market are vying to develop this new form of insulin delivery.
Already, Exubera (Pfizer and Netkar) has become the first inhaled insulin to enter the market, while Novo Nordisk is pursuing final clinical studies on AerX with plans to launch it by 2008.
However, the inhaled insulin market faces concerns over the long-term safety and efficacy of using the pulmonary insulin delivery method.
Occurrences of pulmonary fibrosis during clinical trials and the incidence of side effects are restraining the uptake of inhaled insulin.
In addition, due to high production costs, inhaled insulins are likely to be priced three to five times higher than conventional ones.
This price premium will challenge manufacturers, although the price factor will be balanced out by its greater convenience.
"As the European markets are driven by the convenience factor, companies will need to analyse dosing accuracy, bioavailability and the device size," says Ms Findlay: "This novel drug delivery method will have to demonstrate its advantages in terms of safety and accuracy relative to current insulin injections".
The ability to prove its safety and convenience will determine the uptake of the inhaled insulin method.
Manufacturers of inhaled insulin devices will need to focus on the long-term safety and convenience aspects of their products, with the incorporation of newer techniques in inhaler devices set to enhance convenience.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the Diabetes Drug Delivery Methods-Market and Technologies, please apply to Frost and Sullivan.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
